Angioplasty Clinical Trials

Clinical trials related to Angioplasty Procedure

Use of mechaNical Left ventricuLar unlOADing in Complex Higher-risk Indicated Procedures

Status: Recruiting
Location: See all (8) locations...
Intervention Type: Device
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

If there is a narrowing or blockage in the coronary arteries of the heart, the cardiologist may choose to treat this blockage. This is called percutaneous coronary intervention (PCI), which involves both balloon angioplasty and the placement of a stent. PCI is a commonly performed and safe procedure. However, in your case, the procedure is more complicated than usual due to the location and nature of the narrowing, the required technique for the intervention, and the fact that your heart function is reduced. As a result, your PCI will carry a higher risk than usual. During the procedure, balloons are inflated to clear the blockage, and a stent is placed to keep the artery open. This temporarily reduces or even stops the blood and oxygen supply to a large portion of the heart. This moment presents a higher risk for complications, such as low blood pressure or cardiac arrest. As a result, the heart may not pump blood effectively throughout the body, which can lead to oxygen deprivation in other organs. To help the heart in this situation, it is possible to insert a mechanical heart pump during the procedure. This form of support is introduced via an artery in the groin into your left ventricle. The pump helps the heart function and may improve the circulation to the body's organs. On the other hand, the placement of the pump increases the chance of complications. Therefore, there are both potential benefits and risks. It is currently unclear whether PCI with the temporary pump can be performed more safely than without it. This study aims to investigate whether mechanical circulatory support, specifically with the Pulsecath iVAC2L, leads to improved outcomes for patients undergoing high-risk PCI.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:

• Age ≥18 years AND

• Multidisciplinary heart team consensus for high risk PCI +/- MCS AND

• Hemodynamically stable (SCAI A-B) AND

• LVEF \<30% OR LVEF \<35% with moderate MR OR LVEF \<40% with severe MR AND

• Complex left main disease (calcium modifying techniques deemed necessary OR 2-stent techniques, left dominant system) OR equivalent (ostial LAD and RCX) OR last remaining vessel (native).

Locations
Other Locations
Netherlands
Amsterdam University Medical Center
RECRUITING
Amsterdam
Zuyderland
RECRUITING
Geleen
University Medical Center Groningen
RECRUITING
Groningen
Leiden University Medical Center
RECRUITING
Leiden
Maastricht University Medical Center
RECRUITING
Maastricht
Radboud University Medical Center
RECRUITING
Nijmegen
Haaglanden Medical Center
RECRUITING
The Hague
University Medical Center Utrecht
RECRUITING
Utrecht
Contact Information
Primary
Alexander Nap, MD, PhD
a.nap@amsterdamumc.nl
0031 020 444 4445
Backup
Tijmen H. Ris, MD
t.h.ris@amsterdamumc.nl
0031 020 444 4445
Time Frame
Start Date: 2024-01-25
Estimated Completion Date: 2027-03-01
Participants
Target number of participants: 98
Treatments
No_intervention: Standard-of-Care (without MCS)
Patients will undergo high-risk PCI without upfront use of MCS
Experimental: Pulsecath iVAC2L (with MCS)
Patients will undergo high-risk PCI with upfront use of the Pulsecath iVAC2L (MCS)
Sponsors
Collaborators: Pulsecath BV.
Leads: Amsterdam UMC, location VUmc

This content was sourced from clinicaltrials.gov

Similar Clinical Trials